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PET imaging of metabolism involves many choices, from hardware settings, software
options to animal handling considerations. How to decide what settings or conditions
to use is not straightforward, as the experimental design is dependent on the particular
science being investigated. There is no single answer, yet there are factors that are
common to all experiments that are the subject of this review. From physics to physiology,
there are many factors to consider, each of which can have a significant impact upon
measurements of metabolism in vivo. This review examines the most common factors
related to all types of quantitative PET imaging.
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INTRODUCTION
Biological discovery has moved at an accelerated pace in recent
years, with a significant focus on the transition from in vitro to
in vivo models. With animal models widely used in the basic and
preclinical sciences, finding ways to conduct animal experiments
more accurately and efficiently becomes a key factor in the success
and timeliness of research. As a result, there has been a consider-
able increase in the need to adapt clinical imaging methods, as
well as for novel preclinical molecular imaging technologies for
biomedical research. Molecular imaging technologies use molec-
ular probes or interactions to visualize in vivo processes. Many
of the traditional clinical medical imaging technologies, such
as ultrasound, computed tomography (CT), magnetic resonance
imaging (MRI), single-photon emission computed tomography
(SPECT), and positron emission tomography (PET) have been
adapted for imaging small laboratory animal models [1].
Animal models of human disease are an important research
tool in understanding disease processes and developing novel
treatment strategies. Imaging technologies offer the possibility to
study biochemical processes in a non-invasive manner in vivo.
The biggest advantage of in vivo imaging is that it provides a
bridge from preclinical research to human application in the
clinic, enabling similar and sometimes identical experiments to
be carried out across species. In preclinical research, most often
the mouse is the experimental model of choice, due to many
factors, including fast breeding cycle and decreased housing and
maintenance costs. A great advantage of mice is the relatively
high genetic homology with man and highly developed method-
ology for genetic manipulation. This has led to the development
of wide range of transgenic laboratory animals with customized
genetic expression. The most efficient way of utilizing such mod-
els is through longitudinal studies of the same animals over an
extended period of time. Non-invasive imaging technologies have
proven to be extremely valuable tools in performing such stud-
ies and have created the recent surge in small animal imaging
[2]. Moreover, the possibility to use nude or severe combined
immunodeficiency (SCID) mice with xenografts of human tissue
make the immunodeficient mouse model particularly attractive
for oncology research. In some disciplines, primarily in neuro-
science, rats aremore favorable as animalmodels. The larger brain
size means greater stereotactic accuracy in models involving sur-
gical or other invasive procedures directed toward specific brain
regions (e.g., Parkinson rat model) and better identification of
structures in images that have limited resolution.
Small animal PET is increasingly used to assess efficacy of
therapeutic interventions and to validate the application of both
current and novel radiotracers for translation to humans [3]. The
strength of PET imaging is that it offers quantifiable measures
of the underlying biology. The quantitative units given in either
percent injected dose per gram tissue (%ID/g) or in standardized
uptake values (SUV) are usually extracted from defined regions
(or volumes) of interest drawn around an organ. Another more
sophisticated method is the use of kinetic modeling to quantify
the kinetics of the radiotracer in tissue [4, 5]. All these analyti-
cal methods rely on the fact that PET delivers quantitative and
reproducible images. This review will look at all the factors that
influence the accuracy of quantitative small animal PET imaging.
SCANNER SPECIFIC FACTORS
A variety of dedicated small animal PET scanners have been
developed starting from the 1997 and are now commercially avail-
able from different vendors. The requirements on a PET detector
are (a) high detection efficiency, (b) high spatial resolution, (c)
low dead time, (d) good timing resolution, and (e) good energy
resolution. These requirements led to the development of new
scintillation materials such as LSO or LYSO crystals [6, 7], which
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are now widely used in preclinical systems because of their high
and fast light output. Most of the commercial preclinical scanners
are based on small individual scintillators coupled to photomul-
tipliers such as the microPET R4 and P4 scanners [8, 9], the
microPET Focus family [10, 11], the Inveon scanner [12], the
nanoPET/CT scanner [13], the Triumph®II –PET/SPECT/CT sys-
tem [14], the Super Argus PET/CT [15], the ClearPET scanner
[16] or the Genisys4 system [17, 18]. In contrast to these scan-
ners, which are based on individual small scintillator pixels, the
ALBIRA scanner is made of larger monolithic scintillators, where
the point of interaction is estimated from the scintillation light
spread into the position sensitive photomultiplier [19, 20]. This
scanner offers the advantage of reduced dead areas (higher pack-
ing fraction), due to the missing edges between the crystals. A
completely different scanner design was realized in the quadHI-
DAC small animal PET [21], where the detectors are formed by
multiwire proportial chambers and lead converter plates.
In the following sections, several scanner specific factors that
have an influence on quantitative accuracy are described.
SPATIAL RESOLUTION
In PET, spatial resolution is defined as the distance where two
infinitely small point sources can still be distinguished from each
other. Typical preclinical PET scanners exhibit a spatial resolution
in the order of 1.5–2.5mm measured at full-width at half maxi-
mum (FWHM) of the point spread function in the central field
of view (cFOV). Spatial resolution is critically dependent on the
radial offset, which was recently demonstrated in a study where
the performance evaluation of several preclinical scanners was
performed according to the NEMA NU 4-2008 standards using a
22Na point source [22]. At a radial offset of 5mm the radial spatial
resolution for most of the studied scanners was around 1.6mm
FWHM whereas this value increased to around 2.5mm FWHM
at 25mm radial offset. It was also demonstrated that scanners
with a larger bore size suffer less from this radial elongation effect.
In Table 1 commercially available small animal PET scanners and
the respective spatial resolution values are given.
By reducing the scintillator size from 5mm (human scanners)
to around 1.5mm, the spatial resolution significantly improved.
Still, when looking at the size difference between mice and
humans, which is about 2000, a three-fold decrease in the spatial
resolution is insufficient to create an equal sampling in mice as in
humans. Thus, it still remains difficult to image small structure
sizes of areas such as the mouse brain. This led to the devel-
opment of scanners with even smaller scintillator sizes of only
0.975mm [26, 27]. Smaller crystals means fewer counts per crys-
tal, thus noise and signal strength become significant factors with
this approach. Another issue in PET is that the scanner detects
the point of annihilation and not the point of positron emis-
sion. The positron range in tissue is a function of the kinetic
energy with which it is emitted from the nucleus, which is depen-
dent on the specific isotope [28]. Any residual kinetic energy at
the time of annihilation creates gamma radiation emitted at less
than 180 degrees, resulting in non-collinearity and loss of accu-
rate placement, which is also related to the size of the field of view.
These factors create a fundamental limitation of PET spatial reso-
lution; however there is still room to improve upon the current
PET system designs. Different resolution modeling approaches
have been proposed to account for these physical effects [29, 30]
yet they are only available in their respective academic institu-
tions and are not commercially available. An example of how the
positron range affects image quality is given in Figure 1. Here,
a mini-Derenzo phantom consisting of hollow rods with 2.5,
2.0, 1.5, 1.25, 1.0, and 0.8mm diameter are arranged in six seg-
ments, where the center-to-center distance is equal to two-times
the diameter. The phantom was filled with either a 18F-solution
or a 68Ga-solution. The kinetic energies of the emitted positrons
are 633 keV (18F) and 1.89MeV (68Ga), leading to a clear differ-
ence in mean positron range of around 0.5mm and 3.1mm and
therefore different spatial resolutions [31].
SENSITIVITY
The sensitivity in PET is usually defined as the percentage between
emitted and measured annihilation photons. The sensitivity of a
PET scanner is influenced by the detector material, the dead space
or packing fraction, the crystal length and the solid-angel cov-
erage of the detector ring. Scanners with longer axial FOVs and
smaller bore diameters usually exhibit the highest sensitivity. This
can also be seen in Table 1, where the Inveon scanner with the
rather long axial FOV of 127mm (161mm ring diameter) has a
reported sensitivity of 6.72%, whereas the Genisys4 scanner with
the smaller opening of 50mm combined with a 94mm axial FOV
exhibits an even higher sensitivity of 14%.
The sensitivity plays an important role when imaging receptor
binding probes, where low numbers of receptors are present and
low occupancy rates are needed to avoid pharmacological effects,
thus a low injectable mass of the tracer is required. Depending on
the specific activity and the radiochemical yield, this can lead to
rather low radioactivity concentrations in the injectable volume
of 100μL (some kBq/mL) and thus a high sensitivity is needed.
There is also a tradeoff between sensitivity and resolution.
Smaller crystals enable better resolution; however this means
there are fewer detected events in each individual crystal, which
leads to noisy data and loss of image contrast.
SCATTER
In human PET scans, scatter is a dominant factor with scatter
fractions of up to 36% in septaless full 3D-mode scanners [32].
In small animal PET scanners, the scatter fraction is usually in the
range of ∼8% for a mouse and ∼20% for a rat scan [22]. One
way to increase the throughput of small animal imaging facili-
ties and also to optimize utilization of a radiochemical synthesis
batch (especially for C-11) is to image multiple animals at once
[33]. Several centers are now imaging 2 or up to 8 mice in one
scan [34, 35]. In a recent simulation study [36] it was demon-
strated that the scatter fraction increased by 25% or 64%, when
imaging three or five subjects (MOBY phantom) simultaneously
in comparison to one subject, respectively. This clearly demon-
strates that scatter correction in preclinical imaging is important
when imaging multiple subjects at the same time.
Scatter and also attenuation correction algorithms rely on the
availability of structural information, which can be obtained from
transmission scans using positron (68Ge/68Ga) or single photon
(57Co) emitters or from MR or CT scans. The noise level in
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Table 1 | Characteristics of preclinical PET scanners.
Inveon Mosaic HP ClearPET Argus Genisys4 NanoPET/CT ALBIRA
Siemens Philips Raytest Sedecal Sofie Mediso Bruker
biosciences
Detector material LSO LYSO LYSO/LuYAP LYSO/GSO BGO LYSO LYSO
LYSO/GSO monolithic
Crystal dimension
(mm2)
1.51 × 1.51 × 10 2 × 2 × 10 2 × 2 × 10+ 1.45 × 1.45 × 7 (LYSO); 1.8 × 1.8 × 7 1.12 × 1.12 × 13 40 × 40 × 10
2 × 2 × 10 1.45 × 1.45 × 8 (GSO)
Ring diameter
(mm)
161 197 135–225 118 50+ 181 111
Axial FOV (mm) 127 119 110 48 94 94.8 40
Energy window
(keV)
350–625 385–665 250–650 250–700 150–650 250–750 350–650
Peak detection
efficiency (%)
6.72 2.83 3.03 4.32 14 7.7 2
Transaxial FWHM
resolution at 5mm
(mm)
1.64 2.34 2.02 1.66 1.4* ∼1.6 1.55*
Reference [12] [23] [24] [25] [18] [13] [19]
Reprinted by permission of SNMMI from Goertzen et al. [22], Herrmann et al. [18]: Tables 3, 4 and 1.
+Corresponds to the opening of the PET scanner and not the ring diameter, as the scanner is built up of two flat-panel type detector heads.
*Spatial resolution measured in the central FOV
FIGURE 1 | Emission image of a mini-Derenzo phantom. The phantom
consists of fillable rods with diameters of 0.8, 1.0, 1.25, 1.5, 1.0, and
2.5mm, respectively. Center-to-center distance between adjacent rods was
2 times the rod diameter. The phantom was filled with (A) 18F-solution or a
(B) 68Ga-solution. Images were reconstructed by FORE followed by 2D-FBP.
MR and CT scans is considerably lower than nuclear medicine
based methods, leading to more accurate estimations of scatter
and attenuation corrections.
ATTENUATION CORRECTION
Attenuation of photons absorbed when passing through the sub-
ject and surrounding material (e.g., imaging chamber, bed) is
usually measured using a transmission scan. In small animals,
the amount of tissue through which the 511 keV photons pass
is much smaller as compared to humans, but nevertheless there
is a certain percentage that is lost. For example, photons passing
through the rat’s torso are attenuated by ∼40% [37]. A common
method is to perform a transmission scan before or after the emis-
sion scan using an external source, which is rotating around the
subject (rod or point source) [38]. A conventional approach is to
use a 68Ge/68Ga source working in coincidence mode, where the
detection of the two annihilation photons and the location of the
source form a line of response (LOR). For small animal PET sys-
tems, the use of a single photon emitter source such as 57Co, that
emits photons at a lower energy (122 keV) as compared to the
annihilation radiation has shown to be better suited for attenua-
tion correction (in the absence of a CT). Here the LOR is defined
by the known source location and the photons detected on the
opposing detectors. The advantage of a singles-based approach
is the higher detected photon flux and hence better signal-to-
noise ratio, however this method requires accurate knowledge of
the moving source location. As the energy of the emitted 57Co
photons is lower than 511 keV, the attenuation sinogram values
are scaled up to 511 keV for correction [37]. When using a CT
for attenuation correction, a similar energy scaling approach is
required [38].
Another method for attenuation correction is based on the
segmentation of the PET data, the so called transmissionless
attenuation correction [39]. Here a manual or automatic delin-
eation defines the body edges directly on the emission image, and
by assuming a uniform distribution of attenuation coefficients
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inside the subject an attenuation map is created [40, 41]. The
advantages are that less time is required and no additional dose
is given to the animals (from the CT or transmission scan). The
disadvantages are that they are less accurate in delineating the
subject (especially for radiotracers that are not distributed uni-
formly in the body), provide a less detailed attenuation map and
they do not include the surrounding material like the imaging
chamber. Similar to the rapid switch to PET/CT in clinical sys-
tems, most preclinical systems now utilize both metabolic (PET
or SPECT) and anatomical (MR or CT) multimodality imaging
as the standard protocol, using the anatomical information to
provide scatter and attenuation corrections.
PARTIAL VOLUME EFFECT
Due to the limited spatial resolution of currently available preclin-
ical PET scanners in comparison to the actual size of structures
from rodents (e.g., regions in the brain), partial volume effects
(PVE) are present in the acquired image data. PVE leads to an
underestimation of the activity concentration in the PET images
and spillover into surrounding tissues that is observed in objects
smaller than three times the spatial resolution. In addition, image
sampling where different types of tissue and thus radiotracer con-
centrations are included in one voxel also contributes to PVE
[42–44]. There are several methods for partial volume correction
based either on the count recovery models such as the recovery
coefficient [45, 46] or the contrast recovery coefficient method
[47–49] or they are based on anatomical data (derived from MR
imaging) such as the geometric transfer matrix method [50].
Partial volume correction is an active area of research as most
of the approaches are either not applicable for irregular structures
(hippocampus region in the brain) or they have not been vali-
dated against the true activity values. It has also been shown that
the recovery coefficient is strongly dependent on the count statis-
tics, which is a problem for dynamic studies, where the count rate
changes from time frame to time frame [51]. Together with the
fact that the spatial resolution of the scanner and thus the PVE
is not uniform in the field of view and that PVE is dependent
on the radionuclide and reconstruction algorithm, this make PVE
correction an interesting but complex field of research.
RECONSTRUCTION ALGORITHM
For PET image reconstruction, several rebinning and reconstruc-
tion algorithms are available. In commonly used preclinical PET
systems, the measured coincidences are stored in list mode for-
mat. Then the “raw data” is either converted into 2D sinograms
by applying single-slice rebinning [52], multi-slice rebinning
[53, 54] or Fourier rebinning [55] or into 3D sinograms. The
depth of interaction (DOI) in which an annihilation event occurs
inside the crystals can have a significant impact on image reso-
lution, particularly for small ring systems, thus the positioning
of oblique angle events is important. In single-slice rebinning
(SSRB) the oblique coincidence lines are assigned to a particu-
lar 2D sinogram associated with the transaxial slice lying midway
axially between the detectors. In multi-slice rebinning (MSRB)
a more sophisticated rebinning algorithm is applied, where an
oblique coincidence line contributes to the sinogram of all slices
which it traverses. MSRB is more accurate than SSRB, but is less
stable in the presence of noise [55]. In Fourier rebinning (FORE)
the oblique coincidences are binned to a transaxial slice using
the frequency-distance relationship of the data in Fourier space.
The reconstruction of the stack of sinograms is then performed
using conventional 2D algorithms. The advantage of rebinning
and further 2D reconstruction is that it speeds up reconstruction
time.
The conventional 2D image reconstruction algorithms are
filtered-backprojection (FBP) or 2D ordered-subsets expectation-
maximization (OSEM). Apart from the 2D algorithms, fully 3D
algorithms such as 3D-OSEM or 3D maximum a posteriori
(MAP) [56, 57] or a combination of both can also be applied. The
3D reconstruction algorithms can either work iterative or non-
iterative and process oblique coincidence lines without making
geometrical approximations. The advantages of the 3D algo-
rithms are that they provide images with better spatial resolution
and thus an improved recovery rate as compared to FBP [58, 59],
with the assumption that the noise level is the same. Iterative
methods can also take into account the geometric and spatial
characteristics of the scanner to improve resolution (P matrix).
Iterative reconstruction also avoids mispositioning of activity
outside the animals, creating images without streaking artifacts
commonly seen around the bladder with F-18 labeled probes.
Iterative reconstruction can create noise and artifacts from insuf-
ficient or to many iterations, thus knowing when to stop becomes
a problem, one that is often specific to the imaging probe and
scanner settings used to collect the data. Another example is for
MAP reconstruction, where the spatial resolution is dependent on
the choice of the β hyperparameter (parameter which controls the
weight of the penalty term). By choosing a small β, one can obtain
better spatial resolution at the cost of image noise and artifacts.
The advantage of FBP over MAP or OSEM is the possibility
to define offsets in the x- and y-direction during reconstruction.
Thus when imaging multiple animals, small voxel sizes can still be
achieved just by using a high zoom and the respective offset values
equivalent to the midpoint-position of the animals in the field of
view. DuringMAP andOSEM reconstruction, an offset definition
is not feasible and therefore an individual image generation for
each animal cannot be achieved. Themultiple animals can only be
constructed using a rather low zoom thus leading to a larger voxel
size. To exemplify this for the Inveon PET scanner (Siemens), for
a single mouse scan the usual method for reconstruction is the
use of an 128 × 128 × 159 matrix combined with a zoom of 2
leading to a reduced radial field of view of 4.8 cm and a voxel size
of 0.38 × 0.38 × 0.80mm3. For a multiple mouse scan (4 mice)
the whole field of view is needed and therefore a zoom of 1 can
be used with the 128 × 128 × 159 matrix yielding a voxel size of
0.86 × 0.86 × 0.80mm3 [35]. This increased voxel size will lead
to a lower spatial resolution and therefore a higher partial volume
effect.
ANIMAL SPECIFIC FACTORS
As the animal is our “measurement system” in preclinical imag-
ing, several animal specific factors that affect image quantification
are discussed below. Overall, the biological variability even in the
same strains of animals with the same sex and age is by far larger
(∼15–20%) than all the scanner related factors. Therefore, great
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care should be undertaken to optimize all factors that lead to large
standard deviations in animal research such as temperature, diet,
anesthesia, injectable volumes and many others [60, 61].
ANESTHESIA
In small animal PET, anesthesia is usually necessary to render the
subjects motionless for imaging and to minimize the stress and
discomfort associated with restraining procedures. In addition,
invasive surgical procedures are often required to allow admin-
istration of pharmacological agents or sampling of blood. As a
result, a large number of PET imaging studies in rodents are per-
formed under general anesthesia. For all studies it is assumed that
anesthesia-induced perturbation must be minimized by using as
low doses of anesthetic as possible. The anesthetic method is thus
adjusted to the procedure to ensure the necessary level of anes-
thesia and also compatibility with the purpose of the research. In
most cases, the method of anesthesia that was chosen needs to
be reversible such that the subject recovers to normal activity for
future studies. The most common anesthesia method in PET is
the use of an inhalant anesthetic such as isoflurane mixed in oxy-
gen or air. By constantly adapting the isoflurane level to the depth
of anesthesia and using a humidifier, it is possible to achieve quite
long anesthesia periods of up to several hours without adverse
complications. Another method well suited for short imaging
protocols is the use of injectable anesthetics such as ketamine or
xylazine.
Yet, one has to be aware of the fact that by using anesthesia one
is changing the “measurement system” which is the physiology of
the animal. A recent study investigated the effects of anesthesia in
brain PET research [62]. They showed that depending on the used
anesthetics and animal, radiotracer uptake in brain was either
lower (as for [18F]FDG) or binding potentials were higher dur-
ing isoflurane anesthesia (as for [11C]Raclopride). As isoflurane
alters myocardial glucose metabolism it also affects cardiology
studies using [18F]FDG [63–66]. Also in oncology, the anesthetic
method has a pronounced effect on [18F]FDG or [18F]FLT uptake
in tumors [67–69].
In addition to the anesthetic agent, the carrier gas can also
have a profound effect on the outcome of a study. Typically, the
carrier gas for isoflurane anesthesia is oxygen. For hypoxia stud-
ies, where the hypoxic regions are identified and quantified by
using hypoxia radiotracer, the breathing conditions have a strong
effect on radiotracer retention as shown byMaier et al. [70]. They
demonstrated that during the first hour of [18F]FAZA uptake
the breathing conditions (air or oxygen) had an effect on tumor
uptake. When the mice breathed air, the tumor-to-muscle-ratios
were significantly higher as compared to the oxygen breathing
protocols.
These factors have led to the development of systems that are
capable of imaging conscious animals. One system for conscious
rodent imaging is the RatCAP [71, 72], where a miniaturized PET
camera is mounted directly on the head of rats. Other solutions
for conscious PET imaging are the use of marker-based [73] and
also marker-less head motion tracking systems [74]. The marker-
less system simplifies motion-compensated imaging by avoiding
irritation caused by the attachment of the markers, and also the
need to familiarize animals to the markers. Both systems require
a certain period of time in animal handling for successful motion
tracking imaging experiments (10 days handling, 12 days train-
ing phase using a food reward system to acclimatize the animals
to the burrow and scanner environment). Another option is to
inject conscious animals and wait until uptake and clearance are
essentially complete, then anesthetize and image the animals.
TEMPERATURE
The most important factor when putting an animal under anes-
thesia is temperature control. Mice and rats quickly equilibrate
their internal body temperature to the temperature of what-
ever surface they are placed upon when under anesthesia [75].
Therefore the animals become hypothermic and can easily die
within minutes. Almost every metabolic process is altered by
temperature changes, including enzymatic activity, blood flow,
and muscle activity. Since the goal is usually to measure nor-
mal metabolism, not metabolism under hypothermic conditions,
animals need to have sufficient heat support at all stages of the
experiment. Thus rodents must be warmed throughout the whole
imaging procedure starting around 30min before induction of
the anesthesia till the time when they have fully recovered.
HOUSING CONDITIONS
Often overlooked, the housing conditions for animals can have
a significant impact upon physiology and therefore molecular
imaging results. Since animals spend nearly all of their time in
the vivarium, the conditions are the primary factors that influ-
ence the biology under investigation. The bedding amount, type,
cage changing frequency, light/dark cycle, room temperature and
humidity can affect physiology. In the past several years, caging
system use has been shifting from static filter top to individually
ventilated cages (IVC). These IVC cages allow for multiple health
status and mouse types to be housed adjacent to each other, how-
ever they also impose a new source of cold stress upon the animals
[76]. These are not small effects, as it was shown that the size of
xenograft tumors and FDG uptake can be altered by over 300%
based on caging type and ambient temperature [77]. At a min-
imum, the husbandry conditions need to be reported to enable
reproduction of experimental results [78].
FASTING STATE
Because PET images metabolism, measurements can be depen-
dent on the fasting state of the animals. This is particularly true
for [18F]FDG studies, where the fasting state has an influence on
the study outcome as the endogenous available glucose competes
with [18F]FDG and can therefore reduce uptake into the cells
[66–68]. The duration of the fast, type of food (high fat, special
formulations, etc.) can alter factors such as glucose and amino
acid levels, which in turn can alter PET metabolic signals.
POSTURE
The position of the animals inside the scanner is usually deter-
mined by the investigators and can affect the image results. Several
different imaging chambers are available or provided by vendors
that offer the possibility of a defined environment that includes
anesthesia supply, heating and some fixation devices such as tooth
bars or ear plugs [75]. Apart from using corner posts, where the
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limbs can be fixated for a reproducible position, the use of an
immobilization bed has also been proposed [79]. The posture of
the animal (prone or supine) can have an effect on the outcome
of the imaging study has been demonstrated by Richter et al. [80],
where they studied regional pulmonary blood flow in rats. As
mentioned previously, the position of the animal with respect to
the imaging field of view can also change the data, due to factors
such as DOI and resolution.
MONITORING
Animal Monitoring and supportive care aims to maintain the
animal’s physiological status as near to normal as possible. The
goal is to minimize animal pain and distress by adjusting the
depth of anesthesia and to anticipate any impending compli-
cation. Supportive care includes monitoring of physiological
parameters and analgesia during anesthetic and surgical pro-
cedures. Monitoring of vital signs and potential signs of pain
should be done throughout the whole animal handling proce-
dure. Monitoring can either be performed visual, manually or by
using electronic monitoring systems.
Visual and manual monitoring
Visual monitoring means watching the animal carefully while
under anesthesia. By watching the respiration one can note gross
change in rate and can classify the character of breathing. The
color of mucous membrane and skin is related to the oxygena-
tion state—blue (poor oxygenation), pale (poor blood perfusion).
The general behavior of the animal is also monitored visually.
Manually one can test the jaw tone just by moving the jaw down.
Using palpation, one can feel the heart rate, respiration rate, and
body temperature. By pressing mucous membrane or skin, blood
flow status can be visually assessed by looking for resumption of
color in the skin. Yet, in most preclinical scanners visual and/or
manual monitoring is not possible due to the small bore sizes and
restricted space inside the scanners.
Electronic monitoring
Nowadays, nearly all the equipment available for humanmonitor-
ing is also available for small animal monitoring. These include:
• ECG: small electrodes glued to the paws and tail or invasive
with needles
• Respiration rate: small pneumatic pillow placed under the
abdomen of the animal
• Blood pressure: tail cuff sensor (non-invasive) or positioning
of electrode into major artery (invasive)
• Pulse oxymetry: The clip-on-sensors are typically attached to
the rat foot or the shaved mouse thigh. Other useful locations
include the ankle, paw, wrist, or tail.
• Temperature: rectal probe
Using electronic monitoring is a very reliable tool and also
enables monitoring the animals during scans. Some scanners
(e.g., μPET/CT combined systems) have a very long but narrow
bore and therefore visual or manual monitoring is not possi-
ble. Acceptable limits for all the monitored parameters need to
be established and constant monitoring of the anesthetic state
over time is essential. Some monitoring systems have alarm func-
tions that help identify when problems arise, which is helpful
during experiments where many demands are present for the
investigator’s time.
ADMINISTRATION ROUTES
As PET is based on the administration of a radioligand into a
subject, the administration itself has to be performed reliably.
Animals may be conscious or under anesthesia during the injec-
tion, which can influence themeasurement as discussed in section
Anesthesia. Table 2 presents administration volumes for the com-
monly employed routes in the most frequently used species [81].
They are consensus figures based on published literature and
internal guidelines. Two sets of values are shown in each column:
values on the left are intended as a guide to “good practice” dose
volumes for single or multiple dosing; values on the right define
the recommended needle size for each administration route in the
different animals.
When performing intravenous injections, highly trained per-
sonnel are required in order to deliver all the radioactivity repro-
ducibly from the syringe into the blood stream. Otherwise, the
error rate would be very high as shown by a recent study by
Vines et al, where they evaluated mouse tail vein injections in
a qualitative and quantitative approach [82]. They showed that
the overall rate of successful intravenous injection was 92% (46
out of 50). If one is only interested in a static image at ∼45min
post injection, then this error is not as dramatic as the residual
activity will be slowly absorbed and transported into the blood
stream. For a dynamic study where one is interested in the kinetics
of the radiotracer, a paravenous injection severely confounds the
results.
The issue with reliable tail vein injection in mice has also led
to the development of automatic injection systems, such as the
vascular access system (VAS) [83]. In this system, near infrared
light, image processing techniques, computer controlled motors
and a pressure feedback system was used to insert the needle and
to validate the proper location within the tail vein. A study inmice
showed that the residual activity inside the vein was around 3%,
which was better than the manual injections.
For some tracers (such as FDG), the use of an intraperitoneal
injection might be an alternative to avoid cannulation of the
tail vein [84]. Especially when performing short static scans at
around 45–60min post injections, the activity concentrations in
brain, myocardium, plasma, muscle, liver and also tumors are
Table 2 | Administration routes, volumes and needle sizes considered
good practice.
subcutaneous intraperetoneal intravenous (bolus)
(mL kg−1) (mL kg−1) (mL kg−1)
Mouse 10 25G 10 25–27G 5 26G–28G
Rat 10 25G 10 23G–25G 5 25G–27G
Rabbit 10 23–25G 5 2 23G–25G
Table adapted from Diehl et al. [81] and from the German Society for Laboratory
Animal Science (GV SOLAS).
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comparable [68, 85]. Still, care has to be taken not to inject the
substance into the bowel.
In preclinical imaging another important point is the total
mass of the injected radioligand. This is usually not a con-
cern in human studies, but is much more important in mice.
The injection of too much mass can alter the binding kinet-
ics and therefore the results of the study. For in vivo binding
studies in rodents, the maximal receptor occupancy to fulfill
the tracer kinetic modeling principles should be 10% or even
less [86, 87]. It is therefore important to work with high spe-
cific radioactivity (i.e., the amount of radioactive molecules vs.
unlabeled molecules). A good example of the effect of spe-
cific radioactivity was given by Maeda et al. [88], who per-
formed a study with high specific radioactivity of [11C]PIB
(∼200GBq/μmol) in transgenic Alzheimer mice (APP23).
Reducing the specific activity to around 20GBq/μmol by addi-
tion of cold ligand resulted in profound loss of signal-to-noise
ratio and reduction in binding potential in the hippocampus
and neocortex, along with insensitivity for detection of amyloid
plaques.
Last, the residual activity in the syringe also can contribute
to errors in quantitation. Due to the small volume (100μL)
and especially with lipophilic radiotracers that stick to the walls,
a considerable amount of radioactivity might be present in
the syringe and needle—even after a complete injection of the
tracer. Therefore, the syringe (and any catheters) should be mea-
sured after injection to obtain the accurate amount of injected
radioactivity.
BLOOD SAMPLING
In preclinical PET imaging blood sampling can be performed
to generate an arterial input function for kinetic modeling, to
measure the free fraction of radioligand in plasma and to check
for radioactive metabolites. The amount of blood that can be
sampled depends on the circulating blood volume present in
each species. Table 3 gives the circulating blood volumes and the
recommended maximum blood samples volumes for the most
commonly used species. The recommendations are based on
published work [81, 89] and on information from “in-house”
standard operating procedures. Animal welfare is a prime con-
sideration when blood sampling is approaching limits, however
the scientific impact of an animal’s physiological response also
must be considered because this may affect data interpretation
and validity [90].
There are several sampling sites that can be used to obtain
blood samples (mostly at a single time), such as the lateral tarsal
(saphenous) vein, the sublingual vein, the lateral tail vein, the
retrobulbar plexus or directly by cardiac puncture from the heart.
All these sampling methods should be carried out under general
anesthesia.
For repeated blood sampling a catheterization of a major
artery (e.g., carotid or femoral artery) is recommended [91].
Temporary catheters such as butterfly needles and over-the-
needle cannulae can be used in the short term (working day),
whereas for long-term use surgical implantation of a biocom-
patible catheter is required. These methods allow repeated blood
sampling with minimal distress and discomfort for the animal.
Table 3 | Circulating blood volume and recommended maximum
blood sample volume.
Rat (250g rat) Mouse (25g mouse)
Blood volume 64mL/kg (range 50–70) 74mL /kg (range 70–80)
6.4% BW 6.6% BW
16mL 1.8mL
Safe single sample 1.6mL (10%) max 0.2mL (10%) max
1.2mL (7.5%) 0.1mL (7.5%)
Continuous samples
Day 0.2mL 0.02mL
Week 1.4mL 0.14mL
Table adapted from Diehl et al. [81] and from the German Society for Laboratory
Animal Science (GV SOLAS). BW, body weight.
One confound for blood sampling is the time it takes to get a
sufficient sample and the dispersion that occurs between the sam-
pling site and the area of the animal being investigated. As the
sampling site is typically distant from the investigation site, the
blood activity may not match well with respect to concentration
and time for the target region.
PET DATA QUANTIFICATION
The first steps for obtaining quantitative PET images are to
apply the corrections factors that are usually implemented in
the reconstruction procedure. In most of the scanners, deadtime
and decay correction is already performed during data acquisi-
tion. Normalization, attenuation and scatter correction are done
in sinogram space. To ensure reproducible data (even after long
periods of time) a regular quality control of all these correction
factors together with a calibration procedure to convert counts
into kBq/cc using appropriate phantoms is advisable [78].
SEMI-QUANTITATIVE VALUES
There are two commonly used semi-quantitative methods used
in preclinical PET. The first method is the ratio of the activity
in a tissue (given in kBq/cc or mCi/cc) divided by the decay-
corrected activity injected into the animal (given in kBq or
mCi). This ratio is defined as the percent injected dose per
cubic centimeter (or milliliter) in tissue (%ID/cc or %ID/mL).
Commonly, a density of 1 g/cc in tissue is assumed and there-
fore the uptake is often defined as %ID/g. Another method
which also includes the weight of the animal is the standard-
ized uptake value (SUV) calculated as the %ID/cc multiplied
by the weight (given in g). The resultant number is almost
unitless (actually g/cc or g/mL) and is a crude measure of radio-
tracer uptake into tissue. There are numerous problems with
the use of SUV, such as the dependency on body composition
(fat vs. muscle), varying radiotracer uptake and imaging dura-
tions, endogenous competition and definition of the volume or
region of interest (ROI), which are discussed in detail elsewhere
[92, 93]. Often substantial residual activity may be present at the
injection site and therefore not available for biodistribution, lead-
ing to inaccuracies in the injected dose and SUV values. This is
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particularly true if the site is the tail and outside of the imag-
ing FOV. Several correction schemes, involving blood glucose
level, body surface area, and lean body mass have been proposed
in clinical studies to try to improve the accuracy of the SUV
method and are now being used at some clinical PET centers
[94, 95].
In preclinical PET there are also several methods for the extrac-
tion of the SUV from the volume of interest (VOIs). The most
commonly used method is the extraction of the mean SUV over a
ROI or a VOI. When imaging tumors with necrotic cores, another
way of quantification is the definition of a lower threshold such
as the mean plus 1 SD [96] or the inclusion of voxels exhibiting
>75% of maximum radioactivity [97, 98], as a way to exclude
areas with low tracer uptake. Sometimes, the use of the max SUV
or the “5 hottest voxel” is also reported. The problem in defin-
ing the VOI and extracting the SUV is that this value should be
a reliable representative measure of radiotracer uptake and thus
underlying biology of this specific region.
KINETIC MODELING
Tracer kinetic modeling that describesmathematically themecha-
nism of transport and biochemical reactions of the tracer in tissue
is a method to extract transfer rate constants, volumes of distri-
bution or binding potentials from the radiotracer to the target
[99]. Most of the modeling approaches require taking a series of
blood samples from the animal to provide the time course of the
tracer delivery (called the input function) which is matched to
the PET image of the dynamics of the radiotracer concentration
in local tissue over time. By applying model fitting or regres-
sion analysis the desired biological information can be obtained.
In compartment modeling, the model describes the behavior
of the tracer mathematically using a number of compartments,
each of which represents distinct anatomic, physiologic, or bio-
chemical stage of the behavior of the tracer. Typically the model
can be described using a set of linear first order differential
equations.
Several methods for PET tracer kinetic modeling have been
introduced and are now applied in clinical and preclinical
research. Generally speaking they can be divided into model-
driven methods [99–104] and data-driven methods [105–110].
The model-driven methods include compartmental models that
require the radioactivity concentration in arterial blood or
plasma, the so-called “input function,” and reference tissue mod-
els, where the target tissue time-activity curve is expressed as a
function of the reference tissue time-activity curve. In contrast to
the compartmental models based on the input function, which
can be applied to all areas of research, reference tissue models
are primarily used in neuroimaging [111]. The requirement for
using a reference tissue model is that there must be a region in
the brain that is devoid of receptors and representative of the
blood time activity values. This region is then used as an indi-
rect input function to the target region. The data-driven methods
include graphical analysis or spectral analysis. Graphical analy-
sis methods such as Logan and Patlak plots [105–108, 110] use
a transformation of the data such that a linear regression of the
transformed data yields the desired parameters. These methods
are simple and elegant, yet they may be biased by statistical noise
[112], the definition of the starting point for the linear regression
is variable and they also fail to provide information about the
underlying compartmental structure. A more detailed descrip-
tion together with the mathematical background can be found
elsewhere [113–115].
GUIDANCE ON IMAGING STUDIES
A good description on the methods used in preclinical studies
is given by Stout et al. [78]. This paper focuses on the meth-
ods descriptions in manuscripts, however it can also be used as
a “how to do imaging” guide as well. Quantitative preclinical PET
is highly dependent on scanner and animal related parameters.
Therefore, it is difficult to define parameters required to perform
an adequate small animal PET imaging study that are valid for
all studies, as each study design must be optimized based on the
biological target, species used, radiopharmaceutical and scanner
performance.
As an example, for a mouse [18F]FDG oncology study the
following parameter settings seem to be optimal [68]:
• Static scan after 50–60min
• 6-8 h fasting before [18F]FDG injection
• Warm animals before [18F]FDG injection and during the
uptake period
• Isoflurane anesthesia during the injection and uptake period
(optional) and during imaging (required)
The details on how the imaging study was performed are
extremely important when it comes to replication or expand-
ing on existing work from other laboratories. Standardization of
the imaging procedure is particularly essential when pooling data
acquired in different labs.
OPPORTUNITIES
Molecular imaging can help in understanding of biological pro-
cesses behind a particular disease. In central nervous system
(CNS) drug development, the use of translational imaging is
essential for successful clinical proof-of-concept testing [116].
The potential of CNS PET imaging to translate the finding
allows the assessment of target occupancy in preclinical species,
before first-in-human safety and tolerability studies, to refine
dose ranges for exploration in humans. Hargreaves et al. pointed
out that PET imaging has been an important tool for investigating
drug–target interactions and the pathophysiology of many dis-
eases such as monoaminergic dysfunction in schizophrenia and
depression. Especially studies in non-human primates allow a
prediction of the behavior of a drug in humans due to the high
genetic homology [117].
Another area of research where PET has a pivotal role is the
application of molecular imaging to oncology. Using a variety
of radiotracers, different diagnostic targets such as proliferation,
hypoxia, cell surface molecules, tumor vasculature and oxygena-
tion can be assessed [118]. An interesting research area is the use
of imaging for the assessment of early drug response in “mouse
avatars,” where sectioned patient tumor samples are implanted in
immundeficient mice for subsequent use in drug efficacy studies
[119]. The avatars allow for each patient to have their own tumor
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grow in an in vivo system, thereby enabling the identification
of a personalized therapeutic concept. This avatar approach is a
promising concept and has been shown in a murine lung cancer
study that mirrored an ongoing human clinical trial in patients
with KRAS-mutant lung cancers [120]. Using FDG-PET in mice
and patients, they were able to predict antitumor efficacy of doc-
etaxel, selumetinib or combined selumetinib-docetaxel in treating
Kras-mutant lung cancers.
CONCLUSION
PET imaging of metabolism is an excellent research tool that
requires careful consideration of both physical and metabolic
factors in order to obtain meaningful and reproducible informa-
tion. There are many different hardware and software options
that require appropriate selection of options in order to obtain
useful images. The use of animals needs to be carefully consid-
ered with respect to their physiological environmental support to
obtain meaningful metabolic measurements. With proper atten-
tion to the many details involved with PET imaging, reproducible
measurement that have translational potential can be obtained.
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